ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial

Li, Xiang-Meng; Li, Wen-Feng; Lin, Jun-Tao; Yan, Hong-Hong; Tu, Hai-Yan; Chen, Hua-Jun; Wang, Bin-Chao; Wang, Zhen; Zhou, Qing; Zhang, Xu-Chao; Su, Jian; Chen, Rui-Lian; Wu, Yi-Long*; Yang, Jin-Ji*广东省人民医院
Clinical Lung Cancer2021-3DOI: 10.1016/j.cllc.2020.11.001
28被引7阅读
引用收藏
分享

摘要

We investigated the potential use of mutant TP53 in prediction and prognosis of patients with non-small cell lung cancer. We analyzed data obtained from a phase III randomized clinical trial (CTONG 0901). Specific mutations in TP53 (exon 4 or 7) were independently correlated with survival in patients with EGFR mutations. This may help clinicians define precise target populations for treatment. Background: Mutations in TP53 are commonly found in patients with epidermal growth factor receptor (EGFR) mutant advanced non-small-cell lung cancer (NSCLC). In this study, we determined the predictive and prognostic potential of different subtypes of TP53 using data from a phase III randomized trial (CTONG 0901). Patients and Methods: The trial enrolled 195 patients who had undergone next-generation sequencing of 168 genes before treatment with EGFR tyrosine kinase inhibitors. Mutations in TP53 (exon 4 or 7, other mutations, and wild-type) were analyzed based on the therapeutic response and survival. A Cox proportional hazards model was used to determine the potential of the predictive and prognostic factors. Results: All 195 patients harbored activating EGFR mutations: the most common concomitant mutations were TP53 (134/195, 68.7%), CTNNB1 (20/195, 10.3%), and RB1 (16/195, 8.2%). The genetic profiles between patient subgroups administered first-line (132, 67.7%) or later-line (63, 32.3%) treatments did not significantly differ. The median progression-free survival in patients with mutations in exon 4 or 7 of TP53, other TP53 mutations, and wild-type TP53 were 9.4, 11.0, and 14.5 months (P = .009), respectively. Overall survival times were 15.8, 20.0, and 26.1 months (P = .004), respectively. Mutations in exon 4 or 7 of TP53 served as independent prognostic factors for progression-free (P = .001) and overall survival (P = .004) in patients. Conclusion: Mutations in @@@ Background: Mutations in TP53 are commonly found in patients with epidermal growth factor receptor (EGFR) mutant advanced non-small-cell lung cancer (NSCLC). In this study, we determined the predictive and prognostic potential of different subtypes of TP53 using data from a phase III randomized trial (CTONG 0901). Patients and Methods: The trial enrolled 195 patients who had undergone next-generation sequencing of 168 genes before treatment with EGFR tyrosine kinase inhibitors. Mutations in TP53 (exon 4 or 7, other mutations, and wild-type) were analyzed based on the therapeutic response and survival. A Cox proportional hazards model was used to determine the potential of the predictive and prognostic factors. Results: All 195 patients harbored activating EGFR mutations: the most common concomitant mutations were TP53 (134/195, 68.7%), CTNNB1 (20/195, 10.3%), and RB1 (16/195, 8.2%). The genetic profiles between patient subgroups administered first-line (132, 67.7%) or later-line (63, 32.3%) treatments did not significantly differ. The median progression-free survival in patients with mutations in exon 4 or 7 of TP53, other TP53 mutations, and wild-type TP53 were 9.4, 11.0, and 14.5 months (P = .009), respectively. Overall survival times were 15.8, 20.0, and 26.1 months (P = .004), respectively. Mutations in exon 4 or 7 of TP53 served as independent prognostic factors for progression-free (P = .001) and overall survival (P = .004) in patients. Conclusion: Mutations in exon 4 and/or 7 in TP53 are promising predictive and prognostic indicators in EGFR-mutated NSCLC.

学科与关键词

关键词
Mutation spectrumNext-generation sequencingSurvivalTP53 exonTyrosine kinase inhibitor
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Clinical Lung Cancer
发表日期
2021-03
卷期
第 22 卷, 第 2 期
页码
100-+
DOI
10.1016/j.cllc.2020.11.001
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Highlevel Hospital Construction Project [DFJH201809]; National Natural Science Foundation of China [81972164]; Natural Science Foundation of Guangdong Province [2019A1515010931]; National Key Technology R&D Program of the Ministry of Science and Technology of China: Prevention and Control of Major Noncommunicable Diseases [2016YFC1303304]; Key Lab System Project of Guangdong Science and Technology Department - Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • L

    Li, Xiang-Meng (第一作者)

  • L

    Li, Wen-Feng

查看全部 14 位作者收起作者
  • L

    Lin, Jun-Tao

  • Y

    Yan, Hong-Hong

  • T

    Tu, Hai-Yan

  • C

    Chen, Hua-Jun

  • W

    Wang, Bin-Chao

  • W

    Wang, Zhen

  • Z

    Zhou, Qing

  • Z

    Zhang, Xu-Chao

  • S

    Su, Jian

  • C

    Chen, Rui-Lian

  • W

    Wu, Yi-Long (通讯)

    2 · guangdong prov peoples hosp

  • Y

    Yang, Jin-Ji (通讯)

    2 · guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417